AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

NCT04147949 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease
Dyskinesia, Medication-Induced
L-Dopa Causing Adverse Effects in Therapeutic Use

Interventions

DRUG: AV-101
DRUG: Placebo

Sponsor

VistaGen Therapeutics, Inc.